Shanghai Kehua Bio-Engineering announced that it is expected to incur a net loss of CNY 40 to 57 million in the first half of the year, compared to a profit of CNY 21.1281 million in the same period last year. The company's performance declined in the first half of the year due to factors such as changes in the market environment, intensified industry competition, and the implementation of centralized procurement policies. At the same time, the company maintained a high proportion of R&D investment against the market trend and carried on promoting product upgrades, cost reduction, efficiency improvement, layout new businesses and explore new products.
科华生物：预计上半年净亏损4000万元-5700万元
Shanghai Kehua Bio-Engineering: It is expected to have a net loss of 400-570 million yuan in the first half of the year.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.